Home › NDC Lookup › RxCUI directory › RxCUI 2199685

Tenapanor 50 MG Oral Tablet [Ibsrela] — RxCUI 2199685

RxNorm drug concept · Semantic branded drug
RxCUI 2199685 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2199685
Official nameTenapanor 50 MG Oral Tablet [Ibsrela]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asIbsrela 50 MG Oral Tablet
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)32,815 prescriptions · 43 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tenapanor: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It depends on which brand you have. Ibsrela is prescribed for irritable bowel syndrome with constipation — that means belly pain and not being able to go regularly. XPHOZAH is a co...
  • Yes, timing genuinely matters here. Studies showed that taking tenapanor 5 to 10 minutes before a meal — rather than during or after — produces the best effect. For Ibsrela, take i...
  • Why do I need to take it right before eating — does timing really matter?
  • Diarrhea is by far the most common side effect — it happened in about 1 in 6 people taking Ibsrela in clinical trials. You may also notice bloating, gas, or some dizziness. Mild di...
📖 Read our full Tenapanor guide →

🕸️ Concept Web — How Tenapanor 50 MG Oral Tablet [Ibsrela] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Tenapanor 50 MG Oral Tablet [Ibsrela] RxCUI 2199685

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Tenapanor 2199674
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Ibsrela 2199680
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Tenapanor Oral Tablet 2199678
    • Tenapanor Oral Product 2199676
    • Tenapanor Pill 2199677
    • Tenapanor Oral Tablet [Ibsrela] 2199682
    • Ibsrela Oral Product 2199683
    • Ibsrela Pill 2199684
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Tenapanor 50 MG Oral Tablet SCD · 2199679
  • Tenapanor 50 MG SCDC · 2199675
  • Tenapanor Oral Tablet SCDF · 2199678
  • Tenapanor Oral Product SCDG · 2199676
  • Tenapanor Pill SCDG · 2199677

Brand-Name Concepts

  • Tenapanor 50 MG [Ibsrela] SBDC · 2199681
  • Tenapanor Oral Tablet [Ibsrela] SBDF · 2199682
  • Ibsrela Oral Product SBDG · 2199683
  • Ibsrela Pill SBDG · 2199684
  • Ibsrela BN · 2199680

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 2199685 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
73154-0050-06 6 TABLET in 1 BOTTLE (73154-050-06) IBSRELA Ardelyx, Inc. 2019-09-12
73154-0050-60 60 TABLET in 1 BOTTLE (73154-050-60) IBSRELA Ardelyx, Inc. 2019-09-12
Observed labelers: Ardelyx, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$32.5579
Range $32.5579–$32.5579 · middle 50% $32.5579–$32.5579 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.